Oncternal Therapeutics (ONCT) Reports Q1 Loss, Tops Revenue Estimates

Oncternal Therapeutics (ONCT) came out with a quarterly loss of $2.83 per share versus the Zacks Consensus Estimate of a loss of $2.88. This compares to loss of $4 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 1.74%. A quarter ago, it was expected that this biopharmaceutical company would post a loss of $3.09 per share when it actually produced a loss of $3.11, delivering a surprise of -0.65%.Over the last four quarters, the ...